Monocarboxylate transporter 2 (MCT2) is overexpressed in prostate malignant glands, pointing it out as a putative biomarker for prostate cancer. In this study, it was demonstrated that MCT2 localizes mainly at peroxisomes in prostate cancer cells and is able to take advantage of the peroxisomal transport machinery. It was also shown an increase in MCT2 expression from non-malignant to malignant cells that was directly correlated with its peroxisomal localization.
